Merck/Schering-Plough Pharmaceuticals was formed to develop and market new prescription medicines in cholesterol management.

Merck/Schering-Plough currently offers 2 medicines for cholesterol management: VYTORIN^® (ezetimibe/simvastatin) and ZETIA^® (ezetimibe).

Merck/Schering-Plough Pharmaceuticals is a joint venture between Merck & Co., Inc., and Schering-Plough Corporation. The collaboration includes worldwide markets (excluding Japan).

Merck & Co., Inc., is a global research-driven pharmaceutical company dedicated to putting patients first. Merck discovers, develops, manufactures, and markets vaccines and medicines in over 20 therapeutic categories and publishes unbiased health information as a not-for-profit service. For more information, visit merck.com.

Schering-Plough is a global science-based health care company that aspires to earn the trust of doctors, patients, and customers by providing a steady flow of innovative medicines and services that improve the health and well-being of people around the world. For more information, visit schering-plough.com.

This site is intended only for residents of the United States, its territories, and Puerto Rico.

VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. Other brands listed are the trademarks of their respective owners and are not trademarks of MSP Singapore Company, LLC.

Copyright © Merck/Schering-Plough Pharmaceuticals, 2002 - 2009.
All rights reserved.